- Sweden
- /
- Healthtech
- /
- OM:RAY B
Trade Alert: Deputy Chief Executive Officer Of RaySearch Laboratories Bjorn Hardemark Has Sold Stock
We'd be surprised if RaySearch Laboratories AB (publ) (STO:RAY B) shareholders haven't noticed that the Deputy Chief Executive Officer, Bjorn Hardemark, recently sold kr1.9m worth of stock at kr157 per share. In particular, we note that the sale equated to a 67% reduction in their position size, which doesn't exactly instill confidence.
View our latest analysis for RaySearch Laboratories
RaySearch Laboratories Insider Transactions Over The Last Year
In fact, the recent sale by Bjorn Hardemark was the biggest sale of RaySearch Laboratories shares made by an insider individual in the last twelve months, according to our records. That means that an insider was selling shares at around the current price of kr157. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. We note that this sale took place at around the current price, so it isn't a major concern, though it's hardly a good sign.
You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
For those who like to find hidden gems this free list of small cap companies with recent insider purchasing, could be just the ticket.
Does RaySearch Laboratories Boast High Insider Ownership?
Many investors like to check how much of a company is owned by insiders. We usually like to see fairly high levels of insider ownership. It's great to see that RaySearch Laboratories insiders own 24% of the company, worth about kr1.3b. This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.
So What Does This Data Suggest About RaySearch Laboratories Insiders?
An insider hasn't bought RaySearch Laboratories stock in the last three months, but there was some selling. And there weren't any purchases to give us comfort, over the last year. But it is good to see that RaySearch Laboratories is growing earnings. While insiders do own a lot of shares in the company (which is good), our analysis of their transactions doesn't make us feel confident about the company. Therefore, you should definitely take a look at this FREE report showing analyst forecasts for RaySearch Laboratories.
Of course RaySearch Laboratories may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About OM:RAY B
RaySearch Laboratories
A medical technology company, provides software solutions for cancer care in the Americas, Europe, Africa, the Asia-Pacific, and the Middle East.
Flawless balance sheet with high growth potential.